Vor Biopharma Inc. filings document a clinical-stage biotechnology issuer focused on telitacicept and autoimmune disease development. The record includes Form 8-K disclosures for operating and financial results, Regulation FD presentations, clinical and regulatory updates, material agreements, governance changes and capital-structure matters.
Proxy materials describe director elections, equity incentive plan matters, auditor ratification and annual-meeting voting procedures. Other filings address executive compensation arrangements, Nasdaq-listed common stock, a reverse stock split, equity plan share adjustments and security-holder rights tied to the company’s common stock and outstanding awards.
Vor Biopharma Inc. (VOR) is the subject of an amended Schedule 13G in which TCG Crossover Fund II, L.P. and TCG Crossover Fund III, L.P. report beneficial ownership of its common stock. Each fund reports 2,836,539 shares, or 4.6%, with shared voting and dispositive power; TCG Crossover GP II, LLC and TCG Crossover GP III, LLC report power over those same fund-held blocks. Chen Yu, sole managing member of both general partners, reports shared voting and dispositive power over 5,673,078 shares, or 9.2%, comprising the two fund-held blocks. The percentages are based on 61,434,344 shares outstanding as of October 26, 2026. The reporting persons state that they do not constitute a group and disclaim beneficial ownership except as described in the amendment and to the extent of their pecuniary interest.
Vor Biopharma Inc. (VOR) shares were reported as beneficially owned by a group of seven reporting persons, with an aggregate position of 6,443,619 shares as of September 30, 2026, or 9.9% of the class. Each reporting person reported shared voting and dispositive power over that same aggregate. The reporting persons are Venrock Healthcare Capital Partners III, L.P.; VHCP Co-Investment Holdings III, LLC; Venrock Healthcare Capital Partners EG, L.P.; VHCP Management III, LLC; VHCP Management EG, LLC; Nimish Shah; and Bong Y. Koh.
The position comprises common stock and pre-funded warrants immediately exercisable for common shares, held through VHCP III, VHCP Co-Investment III and VHCP EG. Nimish Shah and Bong Y. Koh are voting members of VHCP Management III and VHCP Management EG.
Vor Biopharma Inc. amended its license with RemeGen to add RC298, receiving exclusive rights to develop and commercialize the licensed products outside Greater China. RemeGen received an exclusive, perpetual and irrevocable license under Vor’s intellectual property for Greater China. Vor is responsible for development, regulatory and commercialization activities and costs in its territory.
For the additional products, Vor will pay $10 million cash and issue a pre-funded warrant to purchase 2.3 million common shares at $0.0001 per share. Vor described aggregate upfront consideration of approximately $56 million, including an approximate $46 million warrant value based on its November 11, 2026 closing share price. RemeGen may receive up to $300 million in development and commercial milestones for additional products, up to $330 million in regulatory milestones for initial licensed products, and up to $3.775 billion in sales milestones across all licensed products.
RC298 is in IND-enabling development, with an IND submission in China anticipated in the first half of 2027. RemeGen will lead preclinical and Phase 1 development in China; after Phase 1, Vor will assume subsequent development, regulatory activities and commercialization outside Greater China. Vor reaffirmed cash runway into early 2029.
Vor Biopharma Inc. (VOR) had two reporting persons, FMR LLC and Abigail P. Johnson, each reporting beneficial ownership of 6,318,525 common shares, or 10.7%, as of September 30, 2026. FMR LLC reported sole voting power over 6,317,873 shares and sole dispositive power over 6,318,525 shares; Abigail P. Johnson reported no sole voting power and sole dispositive power over 6,318,525 shares. Other persons were identified as having rights to dividends or sale proceeds, but none had an interest exceeding 5% of the outstanding common stock.
Vor Biopharma Inc. Chief Medical Officer Jeremy Brett Sokolove had 1,917 shares withheld by the company on November 2, 2026, at $19.25 per share, to satisfy tax withholding obligations tied to vesting of restricted stock units granted November 1, 2025. He directly held 25,983 shares after the transaction.
Vor Biopharma Inc. (VOR) entered into a sales agreement with William Blair & Company, L.L.C. and RBC Capital Markets, LLC to offer and sell common stock from time to time at an aggregate offering price of up to $150,000,000. Sales may be made through at-the-market offerings or negotiated transactions, including block trades; the agents are not required to sell a specific amount. Their commission is up to 3.0% of gross sales.
Vor intends to use net proceeds for working capital, capital expenditures and general corporate purposes, with possible investment in or acquisition of complementary businesses or technologies. An illustrative scenario assumes a sale of 7,173,601 shares at $20.91 per share and shows immediate dilution of $20.79 per share to purchasers. The prior sales agreement expired after $125 million of common stock sales, and no further shares may be sold under it.
Vor’s global Phase 3 trial of telitacicept for generalized myasthenia gravis completed enrollment in September 2026, with topline data anticipated in the first half of 2027. The company plans a global Phase 3 trial in ocular myasthenia gravis, with enrollment anticipated to begin in the first half of 2027.
Vor Biopharma Inc. reported third-quarter results and clinical progress for telitacicept; enrollment in the global Phase 3 generalized myasthenia gravis (gMG) trial was complete in September 2026, with topline data anticipated in the first half of 2027. The company also plans a global Phase 3 ocular myasthenia gravis trial, with enrollment expected to begin in the first half of 2027; its global Sjögren’s disease Phase 3 trial dosed its first patient in March 2026.
Third-quarter net loss was $86.7 million, compared with $812.7 million a year earlier, largely reflecting a smaller warrant-liability fair-value expense; research and development expense rose to $34.5 million from $14.1 million. Cash, cash equivalents and marketable securities were $481.6 million as of September 30, 2026, which management expects to fund planned operations into early 2029. On October 30, 2026, the company entered an at-the-market agreement permitting up to $150.0 million of common-stock sales.
Vor Biopharma Inc. (VOR) reported that an option granted to Andrew Levin under its non-employee director compensation policy, and held for the benefit of RA Capital Healthcare Fund, L.P., was exercised on October 2, 2026. The exercise covered 500 options at an exercise price of $12.80 per share, yielding 500 common shares. Levin is obligated to turn the shares over to the Fund’s adviser, RA Capital Management, L.P., to offset advisory fees owed by the Fund; the reported option position after exercise was 0 shares.
Vor Biopharma Inc. (VOR) has filed an automatic shelf registration statement on Form S-3ASR as a well-known seasoned issuer, allowing it to offer from time to time an indeterminate amount of common stock, preferred stock, debt securities, warrants and units, including securities issuable upon conversion or exercise of those instruments. Specific terms, prices and amounts for each takedown will be set in a future prospectus supplement.
Vor Biopharma is a clinical-stage biopharmaceutical company developing telitacicept for autoimmune diseases, with a global Phase 3 trial in generalized myasthenia gravis underway and a global Phase 3 trial in Sjögren’s disease initiated with first patient dosed in March 2026. Net proceeds from any offerings may be used for working capital, capital expenditures, general corporate purposes and potentially for acquisitions or in-licensing of complementary businesses or technologies.
The company qualifies as both an emerging growth company and a smaller reporting company but, based on non-affiliate market value as of June 30, 2026, expects to cease both statuses on December 31, 2026, after which it will be subject to increased disclosure and governance requirements. Vor’s common stock trades on The Nasdaq Global Select Market under the symbol VOR, and the last reported sale price was $24.24 per share on September 3, 2026.
Vor Biopharma Inc. (VOR) reported that entities associated with RA Capital Management, L.P., a ten percent owner, effected an exercise of a stock option for 1,500 shares of Common Stock on August 24, 2026. The option, with an exercise price of $3.736 per share, was immediately exercisable and is now fully exercised with 0 options remaining for this grant.
The option had been granted to non-employee director Joshua Resnick under Vor Biopharma’s director compensation policy, but under his arrangement with RA Capital, any stock received upon exercise is turned over to RA Capital Management, offsetting advisory fees owed by RA Capital Healthcare Fund, L.P. The Adviser, its general partner, the Fund, and individuals Peter Kolchinsky and Rajeev Shah all disclaim beneficial ownership of the option and underlying shares except for any pecuniary interest. The exercise terms reflect a 1-for-20 reverse stock split effected by Vor Biopharma on September 18, 2025.